Skip to content

The application of nalbuphine on transforaminal endoscopic discectomy

The application of nalbuphine on transforaminal endoscopic discectomy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800016509
Enrollment
Unknown
Registered
2018-06-05
Start date
2018-06-01
Completion date
Unknown
Last updated
2018-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lumbar disc herniation

Interventions

trial group:nalbuphine
control group:sufentanil

Sponsors

the Second Affiliated Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Aged > 65 years old male and female; 2. BMI 18.5-30kg/m2; 3. ASA II-III; 4. No sedation or analgesia within 24h preoperative; 5. SPO2>90% when the position is prone; 6. Cooperation with operator; 7. No serious cardiovascular disease, respiratory disease and endocrine disease.

Exclusion criteria

Exclusion criteria: 1. Allergy to anaesthetic; 2. Addicted to sedative or analgesic; 3. Can not cooperation with operator; 4. With serious dysfunction of heart, lung, liver, renal.

Design outcomes

Primary

MeasureTime frame
Behavioral Pain Scale;Rate of the Respiratory depression;

Secondary

MeasureTime frame
basic vital signs;visual analogue scale;operator satisfaction;Nausea and Vomiting in the first 24-hour period;

Countries

China

Contacts

Public ContactGuoweng Niu

the Second Affiliated Hospital of Chongqing Medical University

531684219@qq.com+86 13896076869

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026